CB1R antagonism offers proven therapeutic benefits in multiple metabolic diseases, such as obesity, diabetes, and dyslipidemia, and fibrotic disorders of the liver, heart, kidney, skin, and lung (6). Here, CNR1 is linked to obesity due to melanocortin 4 receptor deficiency.